Alemtuzumab-based reduced-intensity conditioning for XIAP deficiency

Pediatr Int. 2023 Jan-Dec;65(1):e15576. doi: 10.1111/ped.15576.

Authors

Hirokazu Kobushi¹, Katsutsugu Umeda¹, Eitaro Hiejima¹, Kentaro Kato¹, Mayumi Sugimoto², Hirokazu Kanegane³, Junko Takita¹

Affiliations

¹ Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
² Department of Pediatrics, Graduate School of Medical Sciences, Tokushima University, Kyoto, Japan.
³ Department of Child Health and Department, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

PMID: 37534620
DOI: 10.1111/ped.15576

No abstract available

Keywords: XIAP deficiency; alemtuzumab; allogenic hematopoietic cell transplantation; mixed chimerism.

MeSH terms

Alemtuzumab / therapeutic use
Genetic Diseases, X-Linked*
Graft vs Host Disease*
Hematopoietic Stem Cell Transplantation*
Humans
Lymphoproliferative Disorders*
Transplantation Conditioning
X-Linked Inhibitor of Apoptosis Protein

Substances

Alemtuzumab
XIAP protein, human
X-Linked Inhibitor of Apoptosis Protein

Supplementary concepts

Lymphoproliferative Syndrome, X-Linked, 2